Inclusion Criteria:  Age>=18Y; Good Organ Function; Expected survival time ≥ 3 months; Metastatic/recurrent advanced BRAF V600E mCRC that have been diagnosed histologically and have failed first line treatment; At least one measurable lesion as per RECIST v1.1; ECOG score 0-1.  Exclusion Criteria:  Previous treatment with BRAF inhibitors or MEK inhibitors Symptomatic brain or meningeal metastases (unless the patient has been on > treatment for 6 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable). Active clinical severe infection; A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.